Everything below concerns pentadecapeptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-02-28. Numbers and descriptions here follow the published literature rather than marketing material.
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Visual inspection of dry material |
| Solubility | Soluble in water | Polar aqueous solvent class |
| Typical storage | Minus 20 degrees Celsius, desiccated, dark | Applies to the lyophilized form |
| Purity assessment | Reversed-phase HPLC | Ultraviolet detection, area percent |
| Identity confirmation | Mass spectrometry | Measured mass compared with theoretical value |
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
α-Methyl-p-tyrosine (AMPT), or simply α-methyltyrosine, also known in its chiral 2-(S) form as metirosine, is a tyrosine hydroxylase enzyme inhibitor and is therefore a drug involved in inhibiting the catecholamine biosynthetic pathway. AMPT inhibits tyrosine hydroxylase whose enzymatic activity is normally regulated through the phosphorylation of different serine residues in regulatory domain sites. Catecholamine biosynthesis starts with dietary tyrosine, which is hydroxylated by tyrosine hydroxylase and it is hypothesized that AMPT competes with tyrosine at the tyrosine-binding site, causing inhibition of tyrosine hydroxylase. It has been used in the treatment of pheochromocytoma. It has been demonstrated to inhibit the production of melanin. It is available as a generic medication.
In 1962, Meurgues' work came to the attention of the botanist Roger Heim. He tasked her with setting up a scientific laboratory in the Muséum national d'histoire naturelle, dedicated to new methods of conservation and presentation of natural history museum collections. This included conservation techniques such as freeze-drying, and resinous injections, the scientific preservation of colours and pigments, as well as improving the interpretation of exhibitions and displays. She organised and directed the laboratory whilst studying for a Diplôme d'études approfondies (Master's degree) in zoology on Calliphoridae, (types of flies) which she completed in 1973. She was promoted to become the museum's assistant professor, and went on collecting expeditions to Kurdistan, Afghanistan, Kashmir, China, Morocco amongst others. Meurgues organised a number temporary exhibitions including: Les pigments végétaux (Vegetable Pigments) in 1963, Orchidées et plantes épiphytes (Orchids and epiphytic plants) in 1966, Météorites, messagères du cosmos (Meteorites, messengers of the cosmos) in 1968, La Nature au microscope électronique (Nature under an electron microscope) in 1971, Le Sahara avant le désert (The Sahara before the desert) in 1974, Les plus beaux coquillages du monde (The most beautiful shells of the world) in 1975, Histoire naturelle de la sexualité (Natural history of sexuality) in 1977 with André Langaney, a leading French science communicator.
Andexanet alfa is a biologic agent, a recombinant modified version of human activated factor X (FXa). Andexanet alfa differs from native FXa due to the removal of a 34 residue fragment that contains the Gla domain. This modification reduces andexanet alfa's anticoagulant potential. Additionally, a serine to alanine (S419A) mutation in the active site eliminates its activity as a prothrombin to thrombin catalyst, but still allows the molecule to bind to FXa inhibitors. FXa inhibitors bind to andexanet alfa with the same affinity as to natural FXa. As a consequence, in the presence of andexanet alfa, natural FXa is partially freed, which can lead to effective hemostasis. In other words, it acts as a decoy receptor. Andexanet alfa reverses effect of all anticoagulants that act directly through FXa or by binding antithrombin III. The drug is not effective against factor IIa inhibitor dabigatran. Its activity is measured using the anti-Xa test, which is utilized to determine the amount of available factor Xa for coagulation
Samples for dating need to be converted into a form suitable for measuring the 14C content; this can mean conversion to gaseous, liquid, or solid form, depending on the measurement technique to be used. Before this can be done, the sample must be treated to remove any contamination and any unwanted constituents. This includes removing visible contaminants, such as rootlets that may have penetrated the sample since its burial. Alkali and acid washes can be used to remove humic acid and carbonate contamination, but care has to be taken to avoid removing the part of the sample that contains the carbon to be tested.
Sources: en.wikipedia.org
Enantiopure drugs: Some pharmaceuticals show different activity depending on enantiomeric form. L-ribonucleic acid aptamers: Artificial oligonucleotides that are constructed from the mirror-image versions of their natural forms. L-RNA aptamers are highly resistant to degradation by nucleases and are currently being tested in clinical trials. L-glucose, enantiomer of standard glucose: Tests showed that it tastes likes standard sugar, but is not metabolized the same way. However, it was never marketed due to excessive manufacturing costs. More recent research allows cheap production with high yields; however the authors state that it is not usable as a sweetener due to laxative effects.
=== Ion-exchange chromatography === EDTA was used in separation of the lanthanide metals by ion-exchange chromatography. Perfected by F. H. Spedding et al. in 1954, the method relies on the steady increase in stability constant of the lanthanide EDTA complexes with atomic number. Using sulfonated polystyrene beads and Cu2+ as a retaining ion, EDTA causes the lanthanides to migrate down the column of resin while separating into bands of pure lanthanides. The lanthanides elute in order of decreasing atomic number. Due to the expense of this method, relative to countercurrent solvent extraction, ion exchange is now used only to obtain the highest purities of lanthanides (typically greater than 99.99%).
=== Industrial synthesis === Vitamin D3 (cholecalciferol) is produced industrially by exposing 7-dehydrocholesterol to UVB and UVC light, followed by purification. The 7-dehydrocholesterol is sourced as an extraction from lanolin, a waxy skin secretion in sheep's wool. Vitamin D2 (ergocalciferol) is produced in a similar way using ergosterol from yeast as a starting material.
==== Independent law enforcement operations ==== Prior to 2018, the People's Armed Police Border Defense Corps of the Ministry of Public Security Active Service Forces was involved in many anti-drug operations on the China-Myanmar border, where much of the illegal Chinese drug trade is located. In March 25, 2007, 3 PAPBDC officers were killed in action during a shootout with drug traffickers on the China-Myanmar border. Between 2013 and 2023, the China Coast Guard seized a total of 9.875 tonnes of drugs.
where Pb, Th and U are concentrations in parts-per-million, and λ232, λ235 and λ238 are the decay constants of 232Th, 235U and 238U respectively. For chemical dating results to be valid, the following assumptions are required:
Sources: en.wikipedia.org
== Veterinary == In horses, it is sometimes given by injection as an anxiety-relieving medication, though there are many negative common side effects and it is forbidden by many equestrian competition organizations.
=== sea-sef === Sea-Mist Seasonale Seba-Gel Sebcur sebetralstat (INN) Sebizon sebriplatin (INN) secalciferol (INN) secbutabarbital (INN) seclazone (INN) secnidazole (INN) secobarbital (INN) Seconal secoverine (INN) Secran Secreflo secretin (INN) Sectral secukinumab (INN) securinine (INN) Sedapap sedecamycin (INN) Seffin
=== Displacement === After the entire sample is loaded, the feed is switched to the displacer, chosen to have higher affinity than any sample component. The displacer forms a sharp-edged zone at the head of the column, pushing the other components downstream. Each sample component now acts as a displacer for the lower-affinity solutes, and the solutes sort themselves out into a series of contiguous bands (a "displacement train"), all moving downstream at the rate set by the displacer. The size and loading of the column are chosen to let this sorting process reach completion before the components reach the bottom of the column. The solutes appear at the bottom of the column as a series of contiguous zones, each consisting of one purified component, with the concentration within each individual zone effectively uniform.
Ridouan Taghi is the most wanted criminal in the Netherlands. Every time we say or write something about him, there are consequences, attacks and threats. When you are a journalist who writes about him, you take risks of getting murdered. Following this statement, John van den Heuvel was targeted by criminals who planned attacks against him. During a police investigation, a rocket launcher was found in the home of Yassine A., which he had prepared to use on the residence of John van den Heuvel. As a result of this, John van den Heuvel cancelled his television program on RTL Boulevard where he was to participate as the host of a show. A year later he also received death threats from Ridouan Taghi, who was on the run. He warned John van den Heuvel that his name was on Taghi's blacklist. Taghi also placed a bounty on John van den Heuvel for a large sum of money. In December 2019, Ridouan Taghi was eventually arrested in Dubai. Following this event, John van den Heuvel had delivered another statement
Sources: en.wikipedia.org
Dry powder is commonly held at minus twenty degrees Celsius, desiccated and away from light. Cold storage slows degradation of the lyophilized material.
Mass spectrometry establishes the molecular mass, and reversed-phase chromatography reports purity. A certificate of analysis typically combines both results.
Solutions degrade faster than the dry powder, particularly at room temperature. Portioning into single-use aliquots and freezing reduces losses from repeated thawing.
The dry powder is the stable form and the dissolved form is comparatively fragile. Freezing a solution slows degradation but does not stop it, and repeated freezing and thawing adds further stress. Many laboratories therefore prepare small single-use portions rather than storing one large volume.